HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort

被引：0
|
作者：
Lin, Mingxi
Luo, Ting
Zhang, Hui
Yang, Wentao
Zhang, Jian
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Breast Dis Ctr, Chengdu, Sichuan, Peoples R China
[3] Northwestern Univ, Dept Prevent Med, Div Biostat, Chicago, IL USA
[4] Fudan Univ, Dept Breast & Urol Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1021
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers
    Marra, Antonio
    Safonov, Anton
    Drago, Joshua
    Ferraro, Emanuela
    Selenica, Pier
    Gazzo, Andrea
    Curigliano, Giuseppe
    Modi, Shanu
    Razavi, Pedram
    Reis-Filho, Jorge
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2023, 83 (05)
  • [12] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [13] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [14] HER2-Low expression in primary male breast cancer
    Rudlowski, Christian
    Erices-Leclercq, Melanie
    Nobbe, Katleen
    Baldus, Stephan
    Foerster, Robert
    Foerster, Frank
    Lubig, Sabine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 29 - 29
  • [15] HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact
    Turner, Natalie H.
    Di Leo, Angelo
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 947 - 957
  • [16] New treatment options for metastatic HER2-low breast cancer
    Denkert, Carsten
    Lebeau, Annette
    Schildhaus, Hans Ulrich
    Jackisch, Christian
    Rueschoff, Josef
    PATHOLOGIE, 2023, 44 (02): : S53 - S60
  • [17] Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort
    Lefevre, S.
    Lusque, A.
    Joyon, N.
    Arnould, L.
    Penault-Llorca, F.
    MacGrogan, G.
    Treilleux, I.
    Vincent-Salomon, A.
    Haudebourg, J.
    Maran-Gonzalez, A.
    Charafe-Jauffret, E.
    Courtinard, C.
    Franchet, C.
    Verriele, V.
    Brain, E.
    Tas, P.
    Delaloge, S.
    Filleron, T.
    LaCroix-Triki, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [18] HER2-low breast cancer: Evolution from primary breast cancer to relapse
    Miglietta, F.
    Griguolo, G.
    Bottosso, M.
    Giarratano, T.
    Lo Mele, M.
    Fassan, M.
    Cacciatore, M.
    Genovesi, E.
    De Bartolo, D.
    Vernaci, G.
    Conte, P. F.
    Guarneri, V.
    Dieci, M. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S23 - S23
  • [19] A New Scoring Algorithm to Assess the Prognosis of Primary and Metastatic Breast Cancer with HER2-low Expression
    Miao, Jiaxian
    Shang, Jiuyan
    Liu, Yueping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S222 - S224
  • [20] Inter-Metastasis Heterogeneity of HER2-Low in Metastatic Breast Cancer
    Jaffer, Shabnam
    Bhardwaj, Swati
    LABORATORY INVESTIGATION, 2024, 104 (03) : S179 - S180
12345